Entrada Therapeutics, Inc. (TRDA) News

Entrada Therapeutics, Inc. (TRDA): $12.18

-0.76 (-5.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TRDA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter TRDA News Items

TRDA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TRDA News Highlights

  • For TRDA, its 30 day story count is now at 3.
  • Over the past 20 days, the trend for TRDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • PEAR are the most mentioned tickers in articles about TRDA.

Latest TRDA News From Around the Web

Below are the latest news stories about Entrada Therapeutics Inc that investors may wish to consider to help them evaluate TRDA as an investment opportunity.

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference. The panel will be held on Monday, March 7, 2022 at 9:10 a.m. Eastern Time.

Yahoo | February 23, 2022

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | February 4, 2022

5AM Venture Management, LLC Buys Pear Therapeutics Inc, Entrada Therapeutics Inc, Sells ...

Investment company 5AM Venture Management, LLC (Current Portfolio) buys Pear Therapeutics Inc, Entrada Therapeutics Inc, sells Crinetics Pharmaceuticals Inc, Avidity Biosciences Inc, Silverback Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 5AM Venture Management, LLC.

Yahoo | February 3, 2022

Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately. “We are thrilled to recognize the appointment of Jared to General Counsel,” said Dipal Doshi, President and Chief Executive Officer of Entra

Yahoo | January 5, 2022

Entrada Therapeutics (NASDAQ:TRDA) Trading Up 6.9%

Shares of Entrada Therapeutics Inc (NASDAQ:TRDA) were up 6.9% during mid-day trading on Thursday . The company traded as high as $17.27 and last traded at $17.16. Approximately 2,764 shares were traded during trading, a decline of 99% from the average daily volume of 259,330 shares. The stock had previously closed at $16.05. A number []

Transcript Daily | December 23, 2021

Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV) therapeutics as a new class of medicines, today announced that the Company will be added to the Russell 2000 ® and Russell 3000 ® Indexes as part of the planned fourth quarter IPO additions, effective after the U.S. market opens on December 20, 2021.

Intrado Digital Media | December 17, 2021

Entrada Therapeutics (NASDAQ:TRDA) Announces Earnings Results

Entrada Therapeutics (NASDAQ:TRDA) announced its quarterly earnings data on Wednesday. The company reported ($9.78) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.87) by ($8.91), Yahoo Finance reports. Shares of NASDAQ:TRDA traded down $0.78 on Friday, hitting $20.24. The company had a trading volume of 174,328 shares, compared to its average []

Dakota Financial News | December 10, 2021

Entrada Therapeutics EPS misses by $8.95

No summary available.

Seeking Alpha | December 9, 2021

Entrada Therapeutics Reports Third Quarter 2021 Financial Results

Successful completion of upsized $208.7 million Initial Public Offering BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent business updates. “This quarter has been transformational for Entr

Yahoo | December 9, 2021

Entrada Therapeutics Incs (NASDAQ:TRDA) Quiet Period Will End on December 8th

Entrada Therapeutics (NASDAQ:TRDA) quiet period will expire on Wednesday, December 8th. Entrada Therapeutics had issued 9,075,000 shares in its public offering on October 29th. The total size of the offering was $181,500,000 based on an initial share price of $20.00. During Entrada Therapeutics quiet period, insiders and underwriters involved in the IPO are prevented from []

Dakota Financial News | December 1, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.412 seconds.